pp65-fllamp dc
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02465268)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pp65-fllamp dc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03615404 | Phase 1 | Sep 30, 2018 | Duke University, National Institutes of Health (NIH) |
| NCT02465268 | Phase 2 | Aug 1, 2016 | National Cancer Institute (NCI), University of Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2018 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1